All Releases
 |
Intellipharmaceutics Announces Second Quarter 2010 Results
Jul 14, 2010
|
24.3 KB |
|
| |
TORONTO, July 14, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs, today reported the results of operations for the three and six month period...
|
|
Intellipharmaceutics Provides Update on Activities Related to Venlafaxine Hydrochloride Extended Release Capsules
Jul 2, 2010
|
13.8 KB |
|
| |
TORONTO, July 2, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), today announced the following with regard to its generic drug commercialization activities.
Wyeth LLC, a wholly owned subsidiary of Pfizer Inc., filed suit for patent infringement against Intellipharmaceutics in the United States Dist...
|
|
Intellipharmaceutics Files ANDA With the FDA for Generic Protonix(R)
Jun 14, 2010
|
13.5 KB |
|
| |
TORONTO, June 14, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribe...
|
|
Intellipharmaceutics Announces Significant Advance in Its Abuse-Deterrent Oxycodone Program
May 20, 2010
|
16.0 KB |
|
| |
TORONTO, May 20, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced that it has achieved a significant advance in its program to develop and manufacture drugs incorporating abuse-deterrent characteristics. The Company advises that it has taken delivery of and fully qualified its primary manufactu...
|
|
FDA Accepts for Filing Intellipharmaceutics' ANDA for Generic Effexor XR(R)
May 7, 2010
|
13.5 KB |
|
| |
TORONTO, May 7, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of the antidepressant Effexor XR® (venlafaxine hydrochloride).
The Company's application wi...
|
|
Intellipharmaceutics Announces First Quarter 2010 Results
Apr 13, 2010
|
23.6 KB |
|
| |
TORONTO, April 13, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of controlled and targeted novel oral solid drugs, today reported the results of operations for the three month period ended February 28, 2010. All comparative...
|
|
Intellipharmaceutics Announces Settlement for its Generic Version of Focalin XR(R)
Mar 11, 2010
|
14.6 KB |
|
| |
TORONTO, March 11, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U...
|
|
Intellipharmaceutics Announces 2009 Eleven Month Period End Results
Mar 1, 2010
|
24.9 KB |
|
| |
TORONTO, March 1, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a specialty pharmaceutical company focused on difficult-to-formulate drugs, today reported the results of operations for the eleven month period ended November 30, 2009. All comparative information is that of the predecessor company Intellipha...
|
|
Intellipharmaceutics to Host Conference Call and Webcast on March 1, 2010 at 10:00 a.m. Eastern Time
Feb 23, 2010
|
15.9 KB |
|
| |
TORONTO, Feb. 23, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a specialty pharmaceutical company focused on difficult-to-formulate drugs, today announced that it will host a conference call and webcast, including a slide presentation, to discuss its financial results for 2009 and provide a corporate upda...
|
|
Intellipharmaceutics Announces Appointment of Chief Financial Officer
Feb 12, 2010
|
14.7 KB |
|
| |
TORONTO, Feb. 12, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a specialty pharmaceutical company focused on difficult-to-formulate drugs, today announced the appointment of Graham Neil, CA, as Chief Financial Officer and Vice-President, Finance.
Mr. Neil is a Chartered Accountant with over 10 years of ...
|
|
IntelliPharmaCeutics International Inc. Announces Third Quarter 2009 Results of IntelliPharmaCeutics Ltd.
Nov 12, 2009
|
67.0 KB |
|
| |
Toronto, Ontario (November 12, 2009) -- IntelliPharmaCeutics International Inc. (NASDAQ:IPCI; TSX:I) today reported the results of operations for the three and nine months ended September 30, 2009 of IntelliPharmaCeutics Ltd., (the “Predecessor Company”) . The company is filing the September 30, 2009 financial statements of Inte...
|
|
Intellipharmaceutics and Vasogen Inc. Complete Arrangement to Create Publicly-traded Specialty Pharmaceutical Company
Oct 22, 2009
|
15.1 KB |
|
| |
Toronto, Ontario (October 22, 2009) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI; TSX:I), is pleased to announce the completion of its previously announced plan of arrangement with Vasogen Inc. effective today. The shareholders of IntelliPharmaCeutics Ltd. and Vasogen Inc. approved this transaction at their respective shareholder meeting...
|
|
Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company
Aug 17, 2009
|
18.0 KB |
|
| |
Mississauga, Ontario - August 17, 2009 -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) and IntelliPharmaCeutics (IPC) announced today that they have entered into a definitive agreement, subject to shareholder and regulatory approvals, whereby Vasogen will combine with IPC under a plan of arrangement and merger to continue as a publicly-traded entity to be c...
|
|
IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Mar 27, 2008
|
14.3 KB |
|
| |
Toronto, Canada-- (PR Web Newswire) — March 27, 2008 — IntelliPharmaCeutics Ltd. (Delaware) is pleased to announce significant results from a recently completed pilot clinical trial for its new abuse-resistant, alcohol-resistant once-a-day oral oxycodone formulation by its operating company IntelliPharmaCeutics Corp. of Toronto (“...
|
|
IntelliPharmaCeuitics Ltd. Announces Generic Drug Commercialization Activities
Oct 22, 2007
|
11.4 KB |
|
| |
TORONTO, Oct. 22 /CNW/ - IntelliPharmaCeutics Ltd. (the "Company") today announced the following with regard to its generic drug commercialization activities. In late August of this year, we announced that the Company's operating affiliate IntelliPharmaCeutics Corp. ("IntelliPharmaCeutics") had received acceptance from the U.S. Food ...
|
|
IntelliPharmaCeutics Announces Equity Investment by Par Pharmaceutical
Aug 1, 2007
|
11.3 KB |
|
| |
TORONTO, Aug. 1 /CNW/ - IntelliPharmaCeutics Ltd. today announced that Par Pharmaceutical (NYSE: PRX) has made a significant equity investment in the Company. IntelliPharmaCeutics Ltd., through its operating company, IntelliPharmaCeutics Corp., develops, licenses and markets both new and generic controlled-release pharmaceutical products. Par Pharm...
|
| Showing 1-16 of 16 |
Page: 1 |
|
|
